Intalight Secures Over RMB 100 Million in Series D Funding to Accelerate Global Expansion

Recently, following the over 300 million yuan C-round financing in 2023 and the tens of millions of yuan strategic financing from Huaxia Eye,Global High-End Optical Ophthalmic Diagnosis and Treatment Equipment Brand Intalight——Intalight (Henan) Technology Co., Ltd. (hereinafter referred to as "Intalight" or "Intalight") has received another boost from capital, completing a D-round financing of over 100 million yuan recently led by Haitong Capital Co., Ltd., and the funds will be mainly used to increase R&D investment, expand product lines, and accelerate the layout of overseas markets.

With a world-class R&D team boasting over 20 years of Silicon Valley engineering experience, Intalight has built world-leading, integrated software and hardware technology and product competitiveness.Within a year, Intalight has completed multiple rounds of financing, with a total amount exceeding 400 million yuan. The investors include top financial investment institutions in China such as Guoshou Equity, Qianhai Ark, CD Capital, Shenzhen Venture Capital, CICC Huirong, Lingang Blue Bay, as well as two major ophthalmology industry investors, Aier Healthcare and Huaxia Eye.. This investment by Haitong Capital not only provides a stronger foundation for the company's product development and market expansion, but also injects new momentum into the growth of Intalight!

Currently, in the Chinese market, Intalight Saiwei Ruyi Full-Eye OCTCumulative sales have broken through 300 units, with over 100 units installed in benchmark hospitals across China and provincial levels., over 80% of the equipment has become the main model, and has maintained a steady growth momentum. According to the public data from hospitals, its OCT products have a leading market share and overall winning bid price among similar brands. In addition, Intalight has collaborated with experts and professors domestically and internationally to publishMore than 110 SCI papers in international journals，becoming a leading enterprise in China's high-end ophthalmic equipment industry.

Based on the established market foundation, as well as the company's technical and market expansion capabilities, Intalight accelerates its global layout. Currently, it has set up a research and development center in Silicon Valley, USA, a sales sub-center in France, and its overseas market team is continuously expanding.Currently, the Intalight Full-Eye OCT has been installed in 13 top ophthalmic centers in Europe and the United States.Among themWell-known hospitals and expert users include: the team of Professor Philip Rosenfeld from Bascom Palmer Eye Institute at the University of Miami, the teams of Professor David Huang and Professor Yali Jia from Casey Eye Institute at Oregon Health & Science University, the team of Professor Ricky Wang from the University of Washington, the team of Professor Robert Chang from Stanford University, the team of French ophthalmic imaging expert Adil EL Maftouhi, the team of Professor Stefan Sacu from the General Hospital of Vienna (AKH), Medical University of Vienna, and so on. In addition to focusing on high-end core markets in Europe and America over the past two years, the company has also expanded into other Asia-Pacific markets outside China recently. For instance, Intalight's full-eye OCT...Famous ophthalmic institutions in the Asia-Pacific region, such as Singapore's Tan Tock Seng Hospital and India's Natasha Eye Center, have also installed the equipment., and more well-known hospitals will be stationed in recently.

Nowadays, Intalight is quickly gaining recognition and becoming a shining star in the global medical technology field with its leading technology and products. The company's success is not only reflected in its outstanding performance in the Chinese market but also in its global strategic layout and ever-expanding international influence.

At the beginning of 2024, Intalight's Full-Eye OCTIntalight Ranks Among the Best Global Fundus Imaging Equipment Brands in Medtech Outlook's 2023 Annual List(Top Retinal Imaging Solutions Provider 2023),” receiving this global honor represents the high recognition from the global ophthalmic academic community for DREAM OCT and also demonstrates its extensive influence in overseas markets.

Over the years, Intalight has continuously deepened its technical accumulation in the ophthalmology field based on a high-level international team.Under the leadership of two founders—Dr. Peng Xianzhao, an expert in optical systems, and Dr. Li Bing, an expert in medical imaging algorithms—Intalight has assembled a world-class, multinational, and interdisciplinary R&D team comprising Silicon Valley semiconductor engineers, top science graduates, and overseas-returning Ph.D.s.Building on this foundation, Intalight continues to launch cutting-edge new products and technologies, maintaining a high pace of innovation. It constantly iterates and sets new standards in image quality, detection rate, and breadth.

In the field of ophthalmic OCT products, Intalight made the world's first commercial launch of a 200,000-speed swept-source OCT in 2019, and for the first time globally, equipped a commercial device with artificial intelligence-based layering technology. In 2020, it launched the world’s first 16.2mm ultra-deep imaging product, setting a new record for the maximum imaging depth of commercial OCT devices. In 2021, Intalight pioneered the world’s first 130° ultra-widefield OCTA, breaking the limit for the largest single-scan range of commercial OCT and expanding its clinical indications. In 2022, the company globally debuted its new product, the "Ruyi Full-Eye OCT," seamlessly integrating five cutting-edge functions—full-eye axial visualization biometry, anterior segment OCT, posterior segment OCT, anterior segment OCTA, and posterior segment OCTA—into one device, ushering in a new era of full-eye OCT. In 2023, Intalight launched the latest generation of its 150° ultra-widefield OCTA product worldwide, pushing OCT technology to new heights.

Intalight Continues to Expand the Application Boundaries of Swept-Source OCT, Extending from Fundus to Refractive and Vision Care Fields. In 2023, it successively launched a revolutionary full-eye swept-source biometry technology with an axial detection rate of over 99% for cataract patients, and a rapid scleral lens fitting solution based on swept-source OCT. These two new technologies have already debuted at major exhibitions in China and attracted industry attention.

However, Intalight did not stop there, butFully leverage the advantages of an international R&D team, and while focusing on ophthalmic diagnostic equipment, continuously advance into the field of ophthalmic treatment equipment with higher technical requirements. New breakthroughs have been made in the ultra-wide-field true color fundus camera with a completely new optical design and the fully femtosecond refractive surgery system.In the future, Intalight will join hands with global ophthalmology experts to launch more world-class technical products, becoming a globally leading ophthalmic device brand. It aims to provide advanced technologies and solutions for ophthalmologists and patients worldwide, illuminating more lives with better vision!